Welcome to The Intel, the Visiopharm Newsletter that brings you our latest news and digital pathology content each month.
As we embrace the new year, we at Visiopharm extend our warmest wishes to you. This edition of The Intel is dedicated to reflecting on the remarkable milestones we achieved together in 2023 and setting our sights on future innovations.
Celebrating scientific impact and collaboration
We're thrilled to share that over 450 scientific publications mentioned Visiopharm's software in 2023. This significant milestone underscores our commitment to advancing scientific discovery and our contribution to the broader scientific community.
Connecting in person
2023 was a year of active engagement for us. We hit the road, attended various industry events, and engaged directly with our valued customers and partners, with whom we collaborated on over 24 posters. We would like to thank everyone involved, from study conception to presentation.
We proudly launched Phenoplex, the first complete workflow for all your multiplexed image analysis needs. If you are using staining technologies such as imaging mass cytometry (Standard BioTools Hyperion XTi™) or high-plex fluorescent panels (Akoya PhenoCycler® or Lunaphore Comet®), Phenoplex is your ideal partner. This workflow seamlessly integrates with these technologies, offering a streamlined approach to analyzing complex multiplex images.
In the EU and the UK, we introduced two IVDR-cleared fully automated clinical workflows for PD-L1 and Ki-67 biomarker assessments, marking a significant step forward for precision pathology.
Commemorating a quarter-century of HER2 targeted therapies, we released a whitepaper on our AI-driven HER2 assessment tool, pivotal in breast cancer diagnostics. Access the whitepaper here.
Additionally, we featured an insightful interview with Dr. Jan Trøst Jørgensen, reflecting on the evolution of HER2-targeted therapies. Read the full interview here.
As we step into another year of innovation and discovery, we remain committed to empowering researchers and pathologists with digital pathology solutions. We look forward to continuing this collaboration with you in 2024.
